BMRN · Biomarin Pharmaceutical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $766.21M | - | $776.13M | $825.41M | $745.14M | - | $745.74M | $712.03M | $648.83M | - |
| Cost of Revenue | $195.00M | - | $140.09M | $150.09M | $151.56M | - | $188.46M | $130.46M | $125.18M | - |
| Gross Profit | $571.21M | - | $636.05M | $675.32M | $593.59M | - | $557.28M | $581.57M | $523.65M | - |
| R&D | $178.80M | - | $409.48M | $161.31M | $158.73M | - | $184.90M | $183.79M | $204.99M | - |
| SG&A | $258.29M | - | $268.42M | $232.28M | $206.12M | - | $253.48M | $263.03M | $225.91M | - |
| Total Operating Expenses | $636.57M | - | $822.83M | $548.52M | $521.25M | - | $631.85M | $591.58M | $560.37M | - |
| D&A | $16.41M | - | $10.60M | $10.60M | $22.07M | - | $10.90M | $11.50M | $27.35M | - |
| Operating Income | $129.64M | - | ($46.69M) | $276.89M | $223.89M | - | $113.89M | $120.45M | $88.46M | - |
| Interest Expense | $2.39M | - | $2.58M | $2.68M | $3.55M | - | $2.97M | $3.57M | $3.55M | - |
| Income Tax | $35.68M | - | $4.42M | $57.34M | $52.40M | - | $28.36M | $24.96M | $16.89M | - |
| Net Income | $105.53M | - | ($30.74M) | $240.53M | $185.69M | - | $106.08M | $107.17M | $88.66M | - |
| EPS - Basic | $0.55 | - | ($0.16) | $1.25 | $0.97 | - | $0.56 | $0.56 | $0.47 | - |
| EPS - Diluted | $0.54 | - | ($0.16) | $1.23 | $0.95 | - | $0.55 | $0.55 | $0.46 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $942.84M | $675.45M | $972.15M | $747.00M | $755.13M |
| Accounts Receivable | $903.91M | $908.21M | $790.27M | $855.86M | $739.18M | $660.53M | $777.55M | $691.23M | $637.16M | $633.70M |
| Inventory | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | $1.11B |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | $2.96B |
| Total Assets | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | $6.84B |
| Current Liabilities | $793.15M | $759.03M | $798.44M | $684.25M | $628.21M | $606.99M | $715.66M | $1.07B | $1.09B | $1.18B |
| Long-term Debt | $597.18M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | $1.89B |
| Stockholders' Equity | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B |
| Retained Earnings | $259.73M | $154.21M | $200.78M | $231.52M | ($9.01M) | ($194.69M) | ($319.64M) | ($425.72M) | ($532.89M) | ($621.55M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $220.65M | - | - | - | $174.39M | - | - | - | $46.97M | - |
| Investing Cash Flow | $725.53M | - | - | - | ($28.24M) | - | - | - | ($14.24M) | - |
| Financing Cash Flow | $813.17M | - | - | - | ($38.78M) | - | - | - | ($42.79M) | - |
| CapEx | $20.92M | - | - | - | $16.77M | - | - | - | $26.10M | - |
| Free Cash Flow | $199.73M | - | - | - | $157.63M | - | - | - | $20.87M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 74.6% | - | 82.0% | 81.8% | 79.7% | - | 74.7% | 81.7% | 80.7% | - |
| Operating margin | 16.9% | - | -6.0% | 33.5% | 30.0% | - | 15.3% | 16.9% | 13.6% | - |
| EBITDA margin | 19.1% | - | -4.7% | 34.8% | 33.0% | - | 16.7% | 18.5% | 17.8% | - |
| Net margin | 13.8% | - | -4.0% | 29.1% | 24.9% | - | 14.2% | 15.1% | 13.7% | - |
| Free cash flow margin | 26.1% | - | - | - | 21.2% | - | - | - | 3.2% | - |
| FCF / Net income | 1.89 | - | - | - | 0.85 | - | - | - | 0.24 | - |
| R&D / Revenue | 23.3% | - | 52.8% | 19.5% | 21.3% | - | 24.8% | 25.8% | 31.6% | - |
| SG&A / Revenue | 33.7% | - | 34.6% | 28.1% | 27.7% | - | 34.0% | 36.9% | 34.8% | - |
| Effective tax rate | 25.3% | - | - | 19.2% | 22.0% | - | 21.1% | 18.9% | 16.0% | - |
| Return on assets | 1.2% | - | -0.4% | 3.2% | 2.6% | - | 1.5% | 1.5% | 1.3% | - |
| Return on equity | 1.7% | - | -0.5% | 4.0% | 3.2% | - | 2.0% | 2.0% | 1.7% | - |
| Return on invested capital | 1.4% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.81 | 5.21 | 4.83 | 5.56 | 5.52 | 5.33 | 4.27 | 3.05 | 2.74 | 2.51 |
| Quick ratio | 4.20 | 3.50 | 3.10 | 3.60 | 3.49 | 3.29 | 2.62 | 1.95 | 1.70 | 1.57 |
| Cash ratio | 2.80 | 1.73 | 1.57 | 1.77 | 1.67 | 1.55 | 0.94 | 0.91 | 0.69 | 0.64 |
| Leverage | ||||||||||
| Debt / Equity | 0.10 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.07 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | 4.09 | - | - | - | - | - | - | - | - | - |
| Interest coverage | 54.3x | - | -18.1x | 103.4x | 63.1x | - | 38.4x | 33.7x | 24.9x | - |
| Equity multiplier | 1.38 | 1.25 | 1.26 | 1.24 | 1.23 | 1.24 | 1.27 | 1.34 | 1.35 | 1.38 |
| Liabilities / Assets | 0.28 | 0.20 | 0.20 | 0.19 | 0.19 | 0.19 | 0.21 | 0.25 | 0.26 | 0.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.10 | 0.11 | 0.10 | - | 0.11 | 0.10 | 0.09 | - |
| Inventory turnover | 0.15 | - | 0.10 | 0.11 | 0.12 | - | 0.16 | 0.11 | 0.11 | - |
| Days sales outstanding | 431d | - | 372d | 378d | 362d | - | 381d | 354d | 358d | - |
| Days inventory outstanding | 2383d | - | 3601d | 3259d | 3070d | - | 2284d | 3312d | 3318d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 104.6x | - | - | 44.7x | 74.4x | - | 127.8x | 149.7x | 189.9x | - |
| P / B | 1.8x | - | 1.7x | 1.8x | 2.4x | - | 2.6x | 3.1x | 3.4x | - |
| P / S | 14.6x | - | 13.4x | 13.1x | 18.6x | - | 18.6x | 23.2x | 26.8x | - |
| EV / EBITDA | 65.3x | - | - | 33.5x | 52.2x | - | 105.6x | 117.7x | 143.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.8% | - | 4.1% | 15.9% | 14.8% | - | 28.3% | 19.6% | 8.8% | - |
| Revenue CAGR (3y) | 8.7% | - | 15.4% | 15.6% | 12.8% | - | 22.2% | 12.4% | 10.1% | - |
| Revenue CAGR (5y) | 9.5% | - | 10.2% | 14.0% | 8.2% | - | 10.1% | 12.9% | 10.1% | - |
| Gross profit growth (YoY) | -3.8% | - | 14.1% | 16.1% | 13.4% | - | 22.1% | 24.5% | 11.4% | - |
| Operating income growth (YoY) | -42.1% | - | - | 129.9% | 153.1% | - | 343.8% | 104.6% | 49.1% | - |
| Net income growth (YoY) | -43.2% | - | - | 124.4% | 109.4% | - | 162.7% | 91.2% | 74.4% | - |
| EPS growth (YoY) | -43.2% | - | - | 123.6% | 106.5% | - | 161.9% | 89.7% | 70.4% | - |
| EPS CAGR (3y) | 26.0% | - | - | 101.7% | 14.7% | - | - | 98.8% | 72.3% | - |
| EPS CAGR (5y) | 43.1% | - | - | - | 16.6% | - | 12.9% | - | - | - |
| FCF growth (YoY) | 26.7% | - | - | - | 655.4% | - | - | - | - | - |
| FCF CAGR (5y) | 17.8% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 7.2% | 7.6% | 11.9% | 14.0% | 14.2% | 14.3% | 10.5% | 10.5% | 8.9% | 7.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$3.22B totalReportable Segment$3.22B · 100.0%
Product / service
$7.49B totalProduct$3.17B · 42.3%
Products Excluding ALDURAZYME$1.10B · 14.7%
VOXZOGO$926.92M · 12.4%
VIMIZIM$792.05M · 10.6%
NAGLAZYME$485.40M · 6.5%
PALYNZIQ$433.31M · 5.8%
ALDURAZYME$208.51M · 2.8%
BRINEURA$186.40M · 2.5%
KUVAN$99.53M · 1.3%
Royalty And Other$53.49M · 0.7%
ROCTAVIAN$35.64M · 0.5%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIOMARIN PHARMACEUTICAL INC against the 5 most active filers in the same SIC group.